drugset / Trial / NCT00437658
Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is designed to assess the effects of elagolix versus subcutaneous depot medroxyprogesterone acetate (DMPA-SC; also known as depo-provera) on bone mineral density (BMD) during treatment for 24 weeks with a subsequent 24-week post-treatment period.
Timeline
- Start
- 2006-12-11
- Primary completion
- 2008-11-24
- Completion
- 2008-11-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elagolix | Small molecule | 75 mg | Oral |
| Subject | Elagolix | Small molecule | 150 mg | Oral |
| Comparator | medroxyprogesterone acetate | Other / unclassified | 104 mg | Subcutaneous |